Keywords: Novartis, Reclast, Osteoporosis, Zolderonic acid, Spine fractures,

Novartis once-yearly Reclast preserves bone mass, provides fracture protection in postmenopausal osteoporosis, long term data show

Article | 18 October 2010

Swiss drug major Novartis (NOVN.VX) presented new six-year data reinforcing the long-term efficacy and safety profile of once-yearly Reclast ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Reclast

zoledronic acid

Go to drug listing